Constellation Pharmaceuticals, Inc.
https://www.constellationpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Constellation Pharmaceuticals, Inc.
ObsEva Ends Linzagolix Launch Plans, Casting Another Shadow Over Women's Health
The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.
As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal
The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.
Stock Watch: Brace For European Biotech Departures From NASDAQ
A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.
Finance Watch: Biopharma IPO Market Silence Continues In The US
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools